Lipocalin 2 performs contrasting, location-dependent roles in APCmin tumor initiation and progression

Evidence that lipocalin 2 (LCN2) is oncogenic has grown in recent years and comes from both animal models and expression analysis from a variety of human cancers. In the intestine, LCN2 is overexpressed in colitis patients and its overexpression is a negative prognostic indicator in colorectal cance...

Full description

Saved in:
Bibliographic Details
Published inOncogene Vol. 32; no. 10; pp. 1233 - 1239
Main Authors Reilly, P T, Teo, W L, Low, M J, Amoyo-Brion, A A, Dominguez-Brauer, C, Elia, A J, Berger, T, Greicius, G, Pettersson, S, Mak, T W
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 07.03.2013
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Evidence that lipocalin 2 (LCN2) is oncogenic has grown in recent years and comes from both animal models and expression analysis from a variety of human cancers. In the intestine, LCN2 is overexpressed in colitis patients and its overexpression is a negative prognostic indicator in colorectal cancer. Functionally, LCN2 has a number of different activities that may contribute to its oncogenic potential, including increasing matrix metalloproteinase activity, control of iron availability and stimulating inflammation. In this report, we examined APCmin intestinal tumorigenesis in an LCN2-deficient background. We found that the loss of LCN2 increased tumor multiplicity specifically in the duodenum, suggesting a potential tumor-suppressive activity. Concurrently, however, LCN2 increased the average small intestinal tumor size particularly in the distal small intestine. We found that this increase was correlated to tumor iron(II) content, suggesting that an iron-scavenging role is important for LCN2 oncogenic activity in the intestine.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0950-9232
1476-5594
1476-5594
DOI:10.1038/onc.2012.159